Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications

키워드

참고문헌 (96)

1. Patsoukis N, "Revisiting the PD-1 pathway", Sci Adv, 6, pp.eabd2712~ (2020)
2. Marin-Acevedo JA, "Next generation of immune checkpoint inhibitors and beyond", J Hematol Oncol, 14, pp.45~ (2021)
3. Anderson AC, "Lag-3, Tim-3, and TIGIT : co-inhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
4. Chihara N, "Induction and transcriptional regulation of the co-inhibitory gene module in T cells", Nature, 558, pp.454~459 (2018)
5. Pedram Yadollahi, "Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity", BMB Reports, 54(1), pp.12~20 (2021), 생화학분자생물학회
6. Yu Y, "Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment", Cell Death Discov, 7, pp.15~ (2021)
7. Byun JK, "Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity", Mol Cell, 80, pp.592~606 (2020)
8. Feng J, "Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1through GPR81 in human lung cancer cells", Oncogene, 36, pp.5829~5839 (2017)
9. Barsoum IB, "A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells", Cancer Res, 74, pp.665~674 (2014)
10. Dong H, "Tumorassociated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
11. Garcia-Diaz A, "interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression", Cell Rep, 19, pp.1189~1201 (2017)
12. Lim SO, "Deubiquitination and stabilization of PD-L1 by CSN5", Cancer Cell, 30, pp.925~939 (2016)
13. Wang X, "Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells", Immunol Lett, 184, pp.7~14 (2017)
14. Quandt D, "Synergistic effects of IL-4 and TNFalpha on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation", J Transl Med, 12, pp.151~ (2014)
15. Xu L, "Inhibition of IL-6-JAK", Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1, Mol Oncol, pp.2018, 12[DOI]
16. Shen MJ, "Radiation alters PD-L1", NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK, Oncotarget, pp.2017, 8[DOI]
17. Chan LC, "IL-6", JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion, 2019, pp.129, 3324~3338
18. Carbotti G, "IL-27induces the expression of IDO and PD-L1 in human cancer cells", Oncotarget, 6, pp.43267~43280 (2015)
19. David JM, "A novel bifunctional anti-PD-L1", TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells, 2017, pp.6, e1349589~
20. Qian Y, "TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells", Cancer Invest, 26, pp.816~821 (2008)
21. Boes M, "TLR3 triggering regulates PD-L1(CD274)expression in human neuroblastoma cells", Cancer Lett, 361, pp.49~56 (2015)
22. Yamashita K, "Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer", Gastric Cancer, 23, pp.95~104 (2020)
23. Shklovskaya E, "Spatial and temporal changes in pd-l1 expression in cancer : the role of genetic drivers, tumor microenvironment and resistance to therapy", Int J Mol Sci, 21, pp.7139~ (2020)
24. Brown JA, "Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production", J Immunol, 170, pp.1257~1266 (2003)
25. Muthumani K, "HIV-mediated phosphatidylinositol 3-kinase", serine-threonine kinase activation in APCs leads to programmed death-1ligand upregulation and suppression of HIV-specific CD8T cells, 2011, pp.187, 2932~2943
26. Kryczek I, "Cutting edge : IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development", J Immunol, 181, pp.5842~5846 (2008)
27. de Kleijn S, "IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1", PLoS One, 8, pp.e72249~ (2013)
28. Schreiner B, "Interferon-beta enhances monocyte and dendritic cell expression of B7-H1(PD-L1), a strong inhibitor of autologous T-cell activation : relevance for the immune modulatory effect in multiple sclerosis", J Neuroimmunol, 155, pp.172~182 (2004)
29. Karakhanova S, "ERK", p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets, 2010, pp.40, 254~266
30. Ou JN, "TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus", Sci Rep, 2, pp.295~ (2012)
31. Hartley G, "Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNFalpha", Cancer Immunol Immunother, 66, pp.523~535 (2017)
32. Zhang W, "IL-6 promotes PD-L1expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma", J Immunother Cancer, 8 (2020)
33. Zhao Q, "Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients", Eur J Immunol, 41, pp.2314~2322 (2011)
34. Xiong HY, "IL-12regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-kappaB signalling", Asian Pac J Cancer Prev, 15, pp.5767~5772 (2014)
35. Jiang C, "Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages", Immunobiology, 222, pp.651~657 (2017)
36. Taube JM, "Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma : implications for PD-1pathway blockade", Clin Cancer Res, 21, pp.3969~3976 (2015)
37. Curiel TJ, "Blockade of B7-H1improves myeloid dendritic cell-mediated antitumor immunity", Nat Med, 9, pp.562~567 (2003)
38. Song S, "Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells", Int Immunopharmacol, 20, pp.117~123 (2014)
39. Ni XY, "TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation", Oncol Rep, 28, pp.615~621 (2012)
40. Pulko V, "TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination", J Immunol, 183, pp.3634~3641 (2009)
41. Huang G, "NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment", PLoS One, 8, pp.e61602~ (2013)
42. Loke P, "PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells", Proc Natl Acad Sci U S A, 100, pp.5336~5341 (2003)
43. Mezzadra R, "Identification of CMTM6 and CMTM4 as PD-L1 protein regulators", Nature, 549, pp.106~110 (2017)
44. Prima V, "COX2", mPGES1, Proc Natl Acad Sci U S A, pp.2017, 114[DOI]
45. Youngnak P, "Differential binding properties of B7-H1 and B7-DC to programmed death-1", Biochem Biophys Res Commun, 307, pp.672~677 (2003)
46. Zhong X, "PD-L2 expression extends beyond dendritic cells", macrophages to B1 cells enriched for V(H)11, Eur J Immunol, pp.2007, 37[DOI]
47. Wang H, "PD-L2 expression in colorectal cancer : Independent prognostic effect and targetability by deglycosylation", Oncoimmunology, 6, pp.e1327494~ (2017)
48. Fu Y, "GATA2 regulates constitutive PD-L1 and PD-L2 expression in brain tumors", Sci Rep, 10, pp.9027~ (2020)
49. Derks S, "Epithelial PD-L2expression marks Barrett’s esophagus and esophageal adenocarcinoma", Cancer Immunol Res, 3, pp.1123~1129 (2015)
50. Latchman Y, "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat Immunol, 2, pp.261~268 (2001)
51. Yamazaki T, "Expression of programmed death 1 ligands by murine T cells and APC", J Immunol, 169, pp.5538~5545 (2002)
52. Huber S, "Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2", Blood, 116, pp.3311~3320 (2010)
53. Inaba K, "Dual roles of PU. 1 in the expression of PD-L2 : direct transactivation with IRF4 and indirect epigenetic regulation", J Immunol, 205, pp.822~829 (2020)
54. Kinter AL, "The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands", J Immunol, 181, pp.6738~6746 (2008)
55. Yu X, "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells", Nat Immunol, 10, pp.48~57 (2009)
56. Masson D, "Overexpression of the CD155 gene in human colorectal carcinoma", Gut, 49, pp.236~240 (2001)
57. Nakai R, "Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma", Cancer Sci, 101, pp.1326~1330 (2010)
58. Bevelacqua V, "Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma", Oncotarget, 3, pp.882~892 (2012)
59. Triki H, "CD155 expression in human breast cancer : clinical significance and relevance to natural killer cell infiltration", Life Sci, 231, pp.116543~ (2019)
60. Hirota T, "Transcriptional activation of the mouse Necl-5", Tage4, CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway, pp.Oncogene, 2005[DOI]
61. Schummer P, "Specific c-Jun target genes in malignant melanoma", Cancer Biol Ther, 17, pp.486~497 (2016)
62. Martinet L, "Balancing natural killer cell activation through paired receptors", Nat Rev Immunol, 15, pp.243~254 (2015)
63. Fionda C, "Nitric oxide donors increase PVR", CD155 DNAM-1 ligand expression in multiple myeloma cells : role of DNA damage response activation, 2015, pp.15, 17~
64. Soriani A, "ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype", Blood, 113, pp.3503~3511 (2009)
65. Fionda C, "The IMiDs targets IKZF-1", 3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma, 2015, pp.6, 23609~23630
66. Gong J, "UPR decreases CD226ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells", Eur J Immunol, 44, pp.3758~3767 (2014)
67. Zitti B, "Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells", Sci Rep, 7, pp.10445~ (2017)
68. Stanietsky N, "Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR", Eur J Immunol, 43, pp.2138~2150 (2013)
69. Chauvin JM, "TIGIT and PD-1 impair tumor antigen-specific CD8(+)T cells in melanoma patients", J Clin Invest, 125, pp.2046~2058 (2015)
70. Kamran N, "Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells", PLoS One, 8, pp.e54406~ (2013)
71. Rangachari M, "Bat3promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion", Nat Med, 18, pp.1394~1400 (2012)
72. Huang YH, "CEACAM1regulates TIM-3-mediated tolerance and exhaustion", Nature, 517, pp.386~390 (2015)
73. Yang R, "Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy", Nat Commun, 12, pp.832~ (2021)
74. Li H, "Tim-3", galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma, 2012, pp.56, 1342~1351
75. Wiener Z, "TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells", J Invest Dermatol, 127, pp.906~914 (2007)
76. Kammerer R, "Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation", J Immunol, 166, pp.6537~6544 (2001)
77. Horst AK, "CEACAM1+myeloid cells control angiogenesis in inflammation", Blood, 113, pp.6726~6736 (2009)
78. Gebauer F, "Carcinoembryonic antigen-related cell adhesion molecules(CEACAM)1, 5 and 6 as biomarkers in pancreatic cancer", PLoS One, 9, pp.e113023~ (2014)
79. Dardalhon V, "Tim-3", galectin-9 pathway : regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells, 2010, pp.185, 1383~1392
80. Zhou J, "Clinicopathological implications of TIM3(+)tumor-infiltrating lymphocytes and the miR-455-5p", Galectin-9 axis in skull base chordoma patients, 2019, pp.68, 1157~1169
81. Yang Q, "microRNA-22downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer", Oncol Rep, 34, pp.1771~1778 (2015)
82. Zhang L, "SUV39H1-DNMT3Amediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer", Cancer Cell Int, 20, pp.325~ (2020)
83. Maruhashi T, "LAG-3inhibits the activation of CD4(+)T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII", Nat Immunol, 19, pp.1415~1426 (2018)
84. Reith W, "Regulation of MHC class II gene expression by the class II transactivator", Nat Rev Immunol, 5, pp.793~806 (2005)
85. Kouo T, "Galectin-3shapes antitumor immune responses by suppressing CD8+T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells", Cancer Immunol Res, 3, pp.412~423 (2015)
86. Xu F, "LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses", Cancer Res, 74, pp.3418~3428 (2014)
87. Wang J, "Fibrinogenlike Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3", Cell, 176, pp.334~347 (2019)
88. Nakahara S, "On the role of galectin-3 in cancer apoptosis", Apoptosis, 10, pp.267~275 (2005)
89. Fei F, "B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3", Oncotarget, 6, pp.11378~11394 (2015)
90. Kim K, "Galectin-3expression in macrophages is signaled by Ras", MAP kinase pathway and up-regulated by modified lipoproteins, 2003, pp.1641, 13~23
91. Liu L, "Nucling mediates apoptosis by inhibiting expression of galectin-3through interference with nuclear factor kappaB signalling", Biochem J, 380, pp.31~41 (2004)
92. Dominguez-Soto A, "The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells", Blood, 109, pp.5337~5345 (2007)
93. Liu Z, "Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactant", Biochem Biophys Res Commun, 365, pp.729~734 (2008)
94. Doroshow DB, "PD-L1 as a biomarker of response to immune-checkpoint inhibitors", Nat Rev Clin Oncol, 18, pp.345~362 (2021)
95. Lee BR, "Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade", JCI Insight, 5, pp.e128633~ (2020)
96. Yonesaka K, "B7-H3negatively modulates ctl-mediated cancer immunity", Clin Cancer Res, 24, pp.2653~2664 (2018)

관련 논문AI추천